12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LDMP: Additional Phase III data

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary reported additional data from a double-blind, U.S. Phase III trial in 606 menopausal women showing that once-daily 7.5 mg LDMP for 12 weeks led to a mean weekly reduction of 33 hot flashes from baseline to week 4 vs. a mean weekly reduction of 23.5 hot flashes for placebo (p<0.0001). At week 12, LDMP led to a mean weekly reduction of...

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >